Abstract

Gadolinium-Based Contrast Agents (GBCA) are intravenous drugs used in diagnostic imaging procedures to enhance the quality of magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA). Recent FDA alerts concerning potential side effects increased patient and medical concerns. We checked if gadolinium remains in the body system longer than pharmaceutical information states and since a growing number of chelation therapists uses chelating agents to remove gadolinium that may have been stored in the body, we checked how effective chelation agents are. Our studies indicate that in the case of gadolinium, chelation does not seem to be an option.

Keywords: Gadolinium; Gadolinium-based contrast agents; GBCA; Chelation; DMPS; DTPA; EDTA